De Waele S, Van Belle S
Department of Medical Oncology, University Hospital Ghent, Ghent, Belgium.
Acta Clin Belg. 2010 Nov-Dec;65(6):378-85. doi: 10.1179/acb.2010.65.6.002.
Cancer-related fatigue (CRF) is the most commonly reported symptom in patients with cancer with a prevalence up to 100%. It has a significant negative impact on quality of life. An effective management of CRF could significantly reduce the disease burden associated with cancer and its treatment. Unfortunately, the underlying pathophysiology is very complex and not uniform. This article reviews the possible therapy of contributing factors, nonpharmacological treatment, such as exercise and psychosocial interventions, and pharmacologic approaches in managing CRF. Numerous drugs, such as psychostimulants (methylphenidate, dexamphetamines, modafinil and pemoline), antidepressants, corticosteroids, L-carnitine, donepezil and guarana have been studied. Methylphenidate, modafinil and guarana show the most promising results so far. However, additional randomized, placebo-controlled trials are needed to determine the benefit of these and other drugs in the treatment of CRF.
癌症相关疲劳（CRF）是癌症患者中最常报告的症状，患病率高达100%。它对生活质量有显著的负面影响。有效管理CRF可显著减轻与癌症及其治疗相关的疾病负担。不幸的是，其潜在的病理生理学非常复杂且不一致。本文综述了在管理CRF方面，对促成因素的可能治疗、非药物治疗（如运动和心理社会干预）以及药物治疗方法。已经研究了许多药物，如精神兴奋剂（哌醋甲酯、右旋苯丙胺、莫达非尼和匹莫林）、抗抑郁药、皮质类固醇、左旋肉碱、多奈哌齐和瓜拉那。哌醋甲酯、莫达非尼和瓜拉那目前显示出最有前景的结果。然而，需要更多随机、安慰剂对照试验来确定这些药物和其他药物在治疗CRF中的益处。
